Discounts Sway NICE As Novartis Outlines Concerns Over New Cancer Drugs Fund
Executive Summary
NICE – the HTA body for England and Wales – has recommended that Novartis's Zykadia (ceritinib) be available on the NHS, but only at a discount. Novartis tells Scrip that with the imminent arrival of the UK's new Cancer Drugs Fund (CDF), there are concerns that access to new cancer drugs will become even more difficult.
You may also be interested in...
NICE Clears Amgen’s Imlygic At Second Attempt, Combo Results Keenly Awaited
A completely new form of therapy, the use of viruses to kill cancer cells, is now recommended by NICE for use in melanoma patients in England in final draft guidance, although its future therapeutic and commercial success may depend on positive findings from ongoing combination studies with checkpoint inhibitors and other immunotherapies.
PCSK9s: Discount Prompts NICE Turnaround on Sanofi's Praluent
HTA body NICE has Okayed PCSK9 inhibitors Repatha and Praluent for adults with primary hypercholesterolaemia or mixed dyslipidaemia for use on the National Health Service IN England and Wales. However, restrictions on prescribing will likely limit sales.
IQWiG: Tafinlar/Mekinist Benefit 'Considerable' In Men With Melanoma, But Still Better In Women
Germany's HTA body IQWiG has declared that there is "an indication of a considerable added benefit for men" of the combination of Novartis' Tafinlar and Mekinist (dabrafenib and trametinib).